SAN CLEMENTE, CA / ACCESSWIRE / February 25, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company’s ReShape VestTM will be discussed during a session at the 4th Annual Surgical Disruptive Technology Summit taking place at the JW Marriott Hotel in Houston, Texas from March 2-4, 2019.
Details of the session:
Date: Saturday, March 2, 2019; 3:50PM – 4:10PM
Presentation Title: “The Gastric Vest as a Novel Weight Loss Procedure: It’s Not a Lapband Either”
Presenter: Jaime Ponce, MD, Bariatric Surgeon, Medical Director of Bariatric Surgery CHI Memorial Hospital, Chattanooga, TN, ASMBS Past-President
About Surgical Disruptive Technology Summit
The Surgical Disruptive Technology Summit, which is hosted by the Department of Surgery at the University of Texas Health Science Center at Houston and the McGovern Medical School, is the pre-eminent educational forum for General, Bariatric, Colorectal, and Oncological Surgeons. The summit is designed to be a place where industry and providers can have an open dialogue about the innovation of surgical technology and surgical practice and where industry participants are welcome and encouraged to voice their opinions right next to surgeons and physicians. The summit is set up in hopes of creating cross talk between the surgical specialties that could lead to new adoption of techniques from specialty to another.
For more details on Surgical Disruptive Technology Summit, please visit https://www.surgicaldisruptivetechsummit.org.
About ReShape Lifesciences Inc.
ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisition of the Lap-Band system, including the risk of default under our security agreement with Apollo Endosurgery entered into in connection with the transaction; our ability to continue as a going concern if we are unable to improve our operating results or obtain additional financing; risks related to ownership of our securities as a result of our delisting from the Nasdaq Capital Market; our proposed ReShape Vest product may not be successfully developed and commercialized; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience; the competitive industry in which we operate; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our vBloc system and Lap-Band system; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission, particularly those factors identified as”risk factors” in our annual report on Form 10-K filed April 2, 2018 and subsequent quarterly reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
Chief Financial Officer
ReShape Lifesciences, Inc.
SOURCE: ReShape Lifesciences Inc.
View source version on accesswire.com: